In November 2022, AK112 received breakthrough therapy designation in conjunction with docetaxel for patients in China suffering from advanced NSCLC and exhibiting resistance to PD‐(L)1 immunotherapy [84]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.